Korean J Pathol.
2000 Aug;34(8):559-566.
Plasminogen Activator Inhibitor-1, c-erbB2, and p53 Protein Overexpression and Prognosis in Gastric Adenocarcinoma
- Affiliations
-
- 1Department of Anatomic Pathology, Soonchunhyang University Hospital, Seoul 140-743, Korea
Abstract
-
Despite its fall in incidence, gastric adenocarcinoma remains a common disease
with dismal prognosis worldwide. A better understanding of its tumorigenesis and
biologic properties of tumor cells related to invasion and metastasis is crucial to
improving diagnosis and treatment. Conflicting results concerning the relationships
between overexpression of PAI-1, c-erbB2, and p53 protein and biologic behavior of
gastric carcinoma have been noted. The aim of this study was to evaluate the value of
overexpression of PAI-1, c-erbB2, and p53 protein as prognostic factors in gastric
adenocarcinoma. Overexpression of PAI-1, c-erbB2, and p53 protein by
immunohistochemistry was correlated with variable clinicopathological parameters and
patients' survival in 80 cases of gastric adenocarcinoma. Overall PAI-1 expression rate
was 63.7% (51/80) and higher in advanced cancer (p=0.0003) and nodal metastasis
(p=0.003) groups. Overall c-erbB2 expression rate was 43.8% (35/80) and higher in
antral (p=0.03), differentiated (p=0.001), intestinal (p=0.0007), and expanding (0.03) groups.
The p53 protein overexpression was 37.5% (30/80) and higher in early cancer (p=0.02),
differentiated (p=0.006) and intestinal groups (p=0.009). Patients with PAI-1, c-erbB2,
and p53 protein positive tumors tended to have poorer survival rates than patients with
PAI-1, c-erbB2, and p53 protein negative tumors, but the difference was not statistically
significant (p=0.25, 0.37, 0.52). Our data indicated that PAI-1 overexpression is one of
the poor prognostic factors in gastric adenocarcinoma and c-erbB2 and p53 protein seem
to be involved in the early stage of carcinogenesis of intestinal type-gastric adenocarcinoma.